Retro Screening¶
Hold a compound query fixed, compare it across many target-associated representations, and prioritize putative biological targets for separate testing.
Core Idea¶
Retro screening is computational target fishing in the compound-to-target direction. A compound, or a defined small set of compounds, is held as the query. The method compares it with representations associated with multiple possible biological targets and prioritizes plausible target associations. A candidate hit is a hypothesis for further inspection or testing, not a demonstrated binding mechanism, adverse effect or treatment.[1][2]
The target side need not be a gallery of protein crystal structures. Rollinger and colleagues screened constituents of Ruta graveolens against a large collection of target-associated pharmacophore models, using both structure-derived and ligand-derived models. Keiser and colleagues compared existing drugs against sets of known ligands for hundreds of targets, using chemical similarity without requiring protein structures. The shared operation is a reverse search across target-indexed alternatives; model construction and scoring differ.[1][2]
Structural Signature¶
- Fixed compound query. A molecule or bounded query set is the object whose possible target profile is sought. One run can be repeated for many compounds, but each comparison retains the compound-to-many-target direction.[1][2]
- Target-indexed collection. Many possible biological targets are represented through pharmacophores, binding-site information, known active ligands or another stated target-linked resource. A protein structure is one option, not a universal requirement.[1][2]
- Comparison rule. A specified fit or chemical-similarity procedure relates the query to each representation. Its scores and thresholds have meaning only under that method's data and calibration.[1][2]
- Prioritized hypotheses. Hits, fit values or statistically ranked associations indicate which targets merit further work. A list of protein names without a comparison rule does not instantiate the method.[1][2]
- Validation boundary. Computational ranking is separate from assays of binding, target function and pharmacological consequences. The cited studies tested selected predictions; experimental testing is not itself required to complete every computational screen.[1][2]
What It Is Not¶
It is not conventional forward virtual screening, which fixes one target and searches a ligand library for candidate binders. Reversing that relation changes which side is queried and what the ranked answer means. It is also not a single compound–protein docking calculation performed after the target was already chosen: the defining search spans target alternatives.[1][2]
Nor does “retro” guarantee a unique algorithm. Pharmacophore fit, ligand-set chemical similarity and structure-based comparisons implement different scoring rules. The original sources do not establish a universal correction for protein-specific scoring bias, nor do they license treating every high-ranked hit as real. Drug repositioning and off-target investigation can use the output, but no clinical outcome is built into the procedure.[1][2]
The live Screening Prime is an economic mechanism in which a menu induces agents with private information to sort themselves. It is a lexical neighbor, not this computational search's parent.
Scope of Application¶
Rollinger and colleagues isolated 16 Ruta graveolens constituents and screened conformations of those molecules against 2,208 pharmacophore models associated with more than 280 targets. The study selected several possible targets for follow-up. Rutamarin was the single virtual hit to a ligand-based CB2-receptor model in that set, and a later radioligand displacement assay found moderate selective CB2 binding in the small tested subset. The authors left agonist-versus-antagonist function unresolved; their limited validation sample does not justify a universal accuracy rate.[1]
Keiser and colleagues queried 3,665 approved or investigational drugs against hundreds of targets represented by known ligand sets. Their chemical-similarity method predicted unexpected associations, of which 30 were experimentally tested and 23 were reported confirmed. One named case was fluoxetine, marketed as Prozac, with beta1 adrenergic receptor antagonism. This is a target-finding and selected-assay result; it does not by itself prove that a particular clinical adverse effect arose from that interaction or that a new indication works.[2]
Other uses may seek a natural product's molecular target, investigate possible off-targets or guide a later repurposing study. The screened collection, method and validation plan must be named for each use.
Clarity¶
State which compound is queried, how candidate targets are represented, how similarity or fit is computed, and what the output does and does not prove. In the Ruta study, the model library mixes structure-based and ligand-based pharmacophores; calling it a complete structural proteome would misdescribe the actual search. In the Keiser study, proteins are indexed by sets of their ligands, so a drug's chemical similarity to a target's ligands supports a tentative target association, not direct observation of binding.[1][2]
Keep method output and follow-up evidence in separate sentences. Rutamarin's virtual CB2 hit preceded a binding assay; the assay tested a selected prediction. Keiser's many predicted associations preceded assays of a subset. Neither paper says every predicted association survived testing.[1][2]
Manages Complexity¶
A compound can be compared with many possible targets, and each target may have several models or known ligands. Retro screening organizes that combinatorial search by keeping the query side fixed, applying a reproducible comparison, then reducing a large target space to candidates for costly follow-up. The Ruta work turns thousands of pharmacophore-model comparisons into a smaller target-focused assay plan; the Keiser work turns many drug–ligand-set comparisons into selected experiments.[1][2]
That reduction is a research triage device, not a proof engine. Model coverage and chemical similarity can miss targets or generate false positives. A ranked list is useful precisely when its data source, scoring meaning and validation limits remain visible.
Abstract Reasoning¶
Begin with a compound whose target profile is in question. Build or choose a collection in which each candidate target is represented by relevant structural or ligand evidence. Compare the same query across target entries under a stated method, prioritize associations, and choose separate assays suited to the biological claim. At every step ask whether an apparent hit arose from the compound, the representation or a scoring artifact.[1][2]
The boundary counterfactual is directional: if the protein target were fixed and the many alternatives were ligands, the procedure would be forward screening. If there were only one preselected compound–target pair, it would be a pairwise prediction or assay. Neither yields a target-fishing profile from a compound query.[1][2]
Knowledge Transfer¶
The method template is compound query → target-indexed collection → comparison scores → prioritized associations → independent follow-up. In the Ruta case, compounds are screened over pharmacophore models and a selected CB2 prediction is tested. In the existing-drug case, drug structures are compared with target ligand sets and selected unexpected associations are tested. The target-side representations and score meanings differ, so a fit value in one study is not interchangeable with a similarity significance in the other.[1][2]
The live Search and Retrieval Prime captures the generic query-to-candidate matching and prioritization relation. Biological target representations and pharmacological validation limits keep this entry domain-specific.
Examples¶
Natural-product target fishing from Ruta graveolens¶
Rollinger and colleagues screened 16 isolated compounds across 2,208 pharmacophore models. For a concrete query, rutamarin matched the ligand-derived CB2-receptor pharmacophore. A later radioligand displacement assay found moderate selective CB2 binding among the small tested subset, while receptor function remained to be determined.[1]
Mapped back: fixed query → rutamarin within the separately screened plant constituents; target collection → many pharmacophore models spanning more than 280 targets; comparison → conformer-to-pharmacophore fit; prioritized output → a CB2 virtual hit; validation boundary → subsequent binding evidence for that selected association, not a general guarantee for all virtual hits.
Existing-drug off-target search¶
Keiser and colleagues compared each drug with ligand sets defining hundreds of targets. Their chemical-similarity search identified unexpected associations; selected assays included fluoxetine antagonism at the beta1 adrenergic receptor. The paper reports 23 confirmed associations among 30 tested, not confirmation of its entire predicted set.[2]
Mapped back: fixed query → one known drug such as fluoxetine; target collection → ligand sets for many proteins; comparison → method-specific chemical-similarity ranking; prioritized output → unexpected target candidates including beta1; validation boundary → selected pharmacological tests, with clinical safety and therapeutic implications requiring separate evidence.
Structural Tensions¶
The two studies demonstrate a prediction-to-validation boundary, not a universal optimization trade-off. Covering more target models can expand the hypotheses returned, but the sources do not establish one necessary cost curve shared by their distinct scoring systems. The core analytical risk is to treat a computational association as an empirical result. No intrinsic trade-off is added merely to fill this section.[1][2]
Diagnostic: Which target association came from the virtual comparison, and which, if any, was separately tested by an assay suited to the claimed mechanism?
Structural–Framed Character¶
Retro Screening is structural within computational pharmacology. Evaluative weight: ranking suggests candidates; a high score is not a verdict about clinical benefit. Human-practice dependence: researchers select libraries, score rules and follow-up tests, but the query-to-target comparison is specified procedurally. Institutional origin: no single software tool or laboratory owns the method family. Vocabulary travel: “screening” in economics, recruitment or medical population testing is not this compound-to-many-target search. Import versus recognition: a new case must demonstrate the reversed search direction, target-indexed resource and tentative output. Its character: a target-finding method nested within computational pharmacology, whose general search-and-retrieval skeleton is already represented by a live Prime.[1][2]
Structural Core vs. Domain Accent¶
The core is the fixed-compound query compared across many target-indexed alternatives to produce provisional target associations. Rutamarin, fluoxetine, CB2, beta1 receptor, pharmacophore fit and ligand-set similarity are accents of the two studies. Remove the target collection or reversed comparison direction and the identity fails; replace a pharmacophore model with a ligand-set representation and it can persist.[1][2]
The portable query–search-space–matching–retrieval structure belongs to the live Search and Retrieval Prime. Target biology, chemical representations and the prediction-versus-assay boundary are this child's stable differentia. A generic “screening” word match does not supply the economics Prime's private-information and self-selection roles.
Instantiates / Related Primes¶
This entry is a kind of Search and Retrieval.
The graph records one strict subsumption edge to Search and Retrieval. The query is the compound, the represented search space is the target-indexed collection, the match rule is chemical similarity or pharmacophore fit, and the retrieved objects are candidate associations. The parent also applies to nonbiological queries. This edge does not call the candidates experimentally established targets.
Drug Repositioning is a possible use of a resulting target hypothesis, not the search method itself. In Silico Experimentation requires intervention in an executable model of a system; static ligand-set or pharmacophore comparison need not meet that condition. Screening in the live Prime catalog is economic self-selection and cannot be used as this entry's direct parent.
Relationships to Other Abstractions¶
Current abstraction Retro Screening Domain-specific
Parents (1) — more general patterns this builds on
-
Retro Screening is a kind of Search and Retrieval Prime
A compound query searches a represented target collection and retrieves prioritized candidate target associations.Every admitted retro-screening run holds a compound or defined small query set fixed, compares it across a larger target-indexed collection by stated relevance criteria, and retrieves putative target associations for prioritization. The live Search and Retrieval Prime covers matching a query to candidates in many search spaces. Compound chemistry, target-associated representations and tentative biological interpretation are the child's stable differentia; retrieval here does not mean empirical confirmation.
Hierarchy paths (4) — routes to 3 parentless roots
- Retro Screening → Search and Retrieval → Problem Space → Representation → Abstraction
- Retro Screening → Search and Retrieval → Trade-offs → Constraint
- Retro Screening → Search and Retrieval → Problem Space → State and State Transition → Phase Space
- Retro Screening → Search and Retrieval → Problem Space → Problem Representation → Representation → Abstraction
Neighborhood in Abstraction Space¶
Retro Screening sits in a sparse region of the domain-specific corpus (97th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.
Family — Protein Structure Prediction & Folding (7 abstractions)
Nearest neighbors
- Substructure Search — 0.82
- Lipinski's Rule of Five — 0.77
- Searching the conformational space for docking — 0.76
- Structural Formula — 0.76
- Epitope mapping — 0.76
Computed from structural-signature embeddings · 2026-10-08
Not to Be Confused With¶
Forward one-target/many-ligand screening: the fixed side is reversed. Pairwise docking: no target-panel search. A confirmed binding assay: empirical evidence after prediction. A measured adverse effect or successful repurposing: a different downstream claim. Mandatory protein structures: ligand-based implementations are attested. A universal scoring correction: method-dependent calibration cannot be assumed from these studies. Economic Screening: a different Prime identity.[1][2]
References¶
[1] J. M. Rollinger, D. Schuster, B. Danzl et al., “In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens”, Planta Medica 75 (2009): 195–204, DOI 10.1055/s-0028-1088397, Methods “Pharmacophore modelling” and “Parallel screening”; Results “Target fishing” and “CB2”, Tables 4–5. Original author manuscript of the published paper; the small CB2 test set cannot support a general predictive-accuracy estimate. registry ↩a ↩b ↩c ↩d ↩e ↩f ↩g ↩h ↩i ↩j ↩k ↩l ↩m ↩n ↩o ↩p ↩q ↩r ↩s ↩t ↩u
[2] M. J. Keiser, V. Setola, J. J. Irwin et al., “Predicting new molecular targets for known drugs”, Nature 462 (2009): 175–181, DOI 10.1038/nature08506, abstract, methods, Fig. 2 and Results. Original author manuscript of the published paper; drug-to-target-ligand-set comparison, selected tests and confirmed associations. Clinical side effects or new treatment efficacy are possibilities for later work, not established by the screen alone. registry ↩a ↩b ↩c ↩d ↩e ↩f ↩g ↩h ↩i ↩j ↩k ↩l ↩m ↩n ↩o ↩p ↩q ↩r ↩s ↩t ↩u